Long-Term Clinical Outcomes of Radical Prostatectomy Versus Image-Guided and Intensity-Modulated Radiation Therapy for Prostate Cancer: A Retrospective and Comparative Study.

IF 1.8 Q3 UROLOGY & NEPHROLOGY
Advances in Urology Pub Date : 2025-03-21 eCollection Date: 2025-01-01 DOI:10.1155/aiu/6412793
Tomoyuki Shimabukuro, Tanaka Hidekazu, Tanabe Masahiro, Takanori Tokunaga, Kosuke Shimizu, Nakanori Fujii, Keita Kobayashi, Hiroshi Hirata, Koji Shiraishi
{"title":"Long-Term Clinical Outcomes of Radical Prostatectomy Versus Image-Guided and Intensity-Modulated Radiation Therapy for Prostate Cancer: A Retrospective and Comparative Study.","authors":"Tomoyuki Shimabukuro, Tanaka Hidekazu, Tanabe Masahiro, Takanori Tokunaga, Kosuke Shimizu, Nakanori Fujii, Keita Kobayashi, Hiroshi Hirata, Koji Shiraishi","doi":"10.1155/aiu/6412793","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background and Objective:</b> The optimal definitive treatment for localized prostate cancer (PCa)-radical prostatectomy (RP) or intensity-modulated radiation therapy with image guidance (IMRTG) remains controversial. This study compares the long-term clinical outcomes of RP and IMRTG in patients with PCa. <b>Methods:</b> We retrospectively analyzed 884 consecutive PCa patients over 25 years. Among them, 610 (69%) underwent RP, while 274 (31%) received IMRTG starting in 2011. The primary objective was to comprehensively assess both treatment modalities. <b>Results:</b> The median age was 68 years in the RP cohort and 73 years in the IMRTG cohort. The median operation time for RP was 4.11 h, with nerve-sparing procedures performed in 45% of cases. Median blood loss was 310 mL, the urinary incontinence rate was 13%, and the median hospital stay was 14 days. In the RP cohort, 46 complications (28%) occurred, including a Grade 4 rectal injury and a Grade 4 wound insufficiency. In the IMRTG cohort, over 80% of patients experienced radiation-induced urological complications, with 11% reporting Grade 2 adverse effects. During a median follow-up of 98 months, there were 79 all-cause deaths and 7 PCa-specific deaths. The 15-year overall survival (OS) rates were 80.9% for RP and 58.3% for IMRTG; however, this difference was not significant in the multivariate analysis, likely due to a higher proportion of high-risk disease in the IMRTG cohort. Approximately 45% of all deaths were attributed to malignant tumors. <b>Conclusions:</b> This long-term retrospective study provides valuable insights into the comparative effects of RP and IMRTG on OS in PCa patients. Both treatments are associated with distinct adverse events, complications, and impacts on urinary continence and sexual function, highlighting the importance of individualized clinical decision-making.</p>","PeriodicalId":7490,"journal":{"name":"Advances in Urology","volume":"2025 ","pages":"6412793"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952913/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/aiu/6412793","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objective: The optimal definitive treatment for localized prostate cancer (PCa)-radical prostatectomy (RP) or intensity-modulated radiation therapy with image guidance (IMRTG) remains controversial. This study compares the long-term clinical outcomes of RP and IMRTG in patients with PCa. Methods: We retrospectively analyzed 884 consecutive PCa patients over 25 years. Among them, 610 (69%) underwent RP, while 274 (31%) received IMRTG starting in 2011. The primary objective was to comprehensively assess both treatment modalities. Results: The median age was 68 years in the RP cohort and 73 years in the IMRTG cohort. The median operation time for RP was 4.11 h, with nerve-sparing procedures performed in 45% of cases. Median blood loss was 310 mL, the urinary incontinence rate was 13%, and the median hospital stay was 14 days. In the RP cohort, 46 complications (28%) occurred, including a Grade 4 rectal injury and a Grade 4 wound insufficiency. In the IMRTG cohort, over 80% of patients experienced radiation-induced urological complications, with 11% reporting Grade 2 adverse effects. During a median follow-up of 98 months, there were 79 all-cause deaths and 7 PCa-specific deaths. The 15-year overall survival (OS) rates were 80.9% for RP and 58.3% for IMRTG; however, this difference was not significant in the multivariate analysis, likely due to a higher proportion of high-risk disease in the IMRTG cohort. Approximately 45% of all deaths were attributed to malignant tumors. Conclusions: This long-term retrospective study provides valuable insights into the comparative effects of RP and IMRTG on OS in PCa patients. Both treatments are associated with distinct adverse events, complications, and impacts on urinary continence and sexual function, highlighting the importance of individualized clinical decision-making.

前列腺癌根治性前列腺切除术与图像引导和调强放疗的长期临床结果:回顾性和比较研究。
背景与目的:局部前列腺癌(PCa)的最佳治疗方法是根治性前列腺切除术(RP)还是图像引导下的调强放疗(IMRTG)仍存在争议。本研究比较了RP和IMRTG治疗PCa患者的长期临床结果。方法:我们回顾性分析了884例连续25年的PCa患者。其中610例(69%)接受RP治疗,274例(31%)从2011年开始接受IMRTG治疗。主要目的是全面评估两种治疗方式。结果:RP组的中位年龄为68岁,IMRTG组的中位年龄为73岁。RP的中位手术时间为4.11小时,45%的病例进行了神经保留手术。中位失血量为310 mL,尿失禁率为13%,中位住院时间为14天。在RP队列中,发生了46例并发症(28%),包括4级直肠损伤和4级伤口功能不全。在IMRTG队列中,超过80%的患者经历了放射引起的泌尿系统并发症,其中11%报告了2级不良反应。在中位随访98个月期间,有79例全因死亡和7例前列腺癌特异性死亡。RP组15年总生存率为80.9%,IMRTG组为58.3%;然而,在多变量分析中,这种差异并不显著,可能是由于IMRTG队列中高风险疾病的比例更高。大约45%的死亡归因于恶性肿瘤。结论:这项长期回顾性研究为RP和IMRTG对PCa患者OS的比较作用提供了有价值的见解。两种治疗方法都有不同的不良事件、并发症以及对尿失禁和性功能的影响,这突出了个性化临床决策的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Urology
Advances in Urology UROLOGY & NEPHROLOGY-
CiteScore
2.90
自引率
0.00%
发文量
17
审稿时长
15 weeks
期刊介绍: Advances in Urology is a peer-reviewed, open access journal that publishes state-of-the-art reviews and original research papers of wide interest in all fields of urology. The journal strives to provide publication of important manuscripts to the widest possible audience worldwide, without the constraints of expensive, hard-to-access, traditional bound journals. Advances in Urology is designed to improve publication access of both well-established urologic scientists and less well-established writers, by allowing interested scientists worldwide to participate fully.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信